HROW HARROW, INC. Insider Trading

Director Graves purchases 1,000 shares of HROW at $31.07; stock down 43.7% from 52-week high amid cluster buying by 2 other insiders in past 14 days.

Director Adrienne L. Graves purchased 1,000 shares at $31.07 on 2026-05-18, establishing an initial position in HARROW, INC. This buy occurs within a cluster pattern: 2 other insiders also purchased shares within the past 14 days. The transaction takes place as the stock trades $30.90, down 43.7% from its 52-week high of $54.85 and 25.5% lower over the past 30 days. HARROW reported $44.2M in quarterly revenue with +36.4% annual growth, yet remains unprofitable with $-27.6M net income in its most recent full fiscal year. The convergence of a new director position acquisition with synchronized insider buying during significant price weakness and an unprofitable operating environment merits examination of what prompted the buy timing and whether valuation or strategic factors are driving the cluster activity.

Director Lauren P Silvernail buys 1,000 shares at $31.00 amid cluster buy; stock down -43.7% from 52-week high.

Lauren P Silvernail, a Director, purchased 1,000 shares at $31.00 on 2026-05-18 at a total value of $31,000.00, establishing an initial 1.0K share position. This transaction is part of a cluster buy pattern, with 3 other insiders also purchasing within the past 14 days. The timing occurs after significant price deterioration: the stock is currently trading at $30.90, down -43.7% from its 52-week high of $54.85 and down -25.5% over the past 30 days. The company reported revenue of $44.2M in its latest quarter but posted a net loss of $-27.6M and is unprofitable on a full-year basis, despite annual revenue growth of +36.4%. Multiple insider purchases concurrent with steep price declines and operational losses warrant investor attention to understand the board's perspective on current valuation and operational trajectory.

HROW CEO Mark L Baum buys 10,000 shares at $30.20; stock down 43.7% from 52-week high amid unprofitability.

CEO Mark L Baum purchased 10,000 shares at $30.20, increasing his holdings to 3.00M shares, at a time when HROW has declined 43.7% from its 52-week high of $54.85 and 35.3% over 90 days. The company remains unprofitable with net income of $-27.6M against quarterly revenue of $44.2M, though annual revenue growth reached 36.4%. Baum's cross-ticker track record shows 3 prior open-market buys with a 90-day win rate of 100.00%, though his same-ticker history at HROW includes only 1 measurable outcome (the 2024-03-22 buy yielded +72.0% over 90 days), with two other HROW purchases lacking measurable outcomes yet. The buy occurs as the stock trades 43.7% below its recent peak, presenting a material disconnect between the CEO's trading activity and the company's current operating loss position.

CFO Andrew R. Boll buys 3,500 shares of HROW at $29.90 amid -35.3% 90-day decline and unprofitable operations

Andrew R. Boll, President and CFO of HARROW, INC., purchased 3,500 shares at $29.90, increasing his holdings from 811.2K to 814.7K shares. The transaction occurred against a backdrop of significant recent stock deterioration: the stock is down 35.3% over 90 days and 43.7% from its 52-week high of $54.85, though the company is growing revenue at 36.4% year-over-year. The company reported negative net income despite $44.2M in latest-quarter revenue, indicating profitability challenges persist despite strong top-line growth. This small open-market purchase by a senior executive in a materially depressed valuation window may warrant monitoring for patterns in follow-on transactions.

Opaleye Management (10% owner) sells 198,572 shares for $7.8M at $39.51 avg; stock down 34.0% from 52-week high, trading near lows.

Opaleye Management, holding 10% of HROW, executed 4 separate sales totaling 198,572 shares (198.6K shares) for $7,846,425.65 ($7.8M) across March 3–4, 2026, reducing its stake by 77.0% from 258,000 shares to 59,428 shares. The sales occurred at a blended average price of $39.51, well above the current price of $36.17, though the stock is down 34.0% from its 52-week high of $54.80 and off 23.4% over the past 30 days. The company's fundamentals show mixed signals: revenue growth of 36.4% year-over-year and quarterly revenue of $71.6M, but the company remains unprofitable on a full-year basis with net income negative, and trades at a P/E of 180.85—a metric meaningful only on the assumption of sustained or increasing profitability. Opaleye's prior open-market sell (1 trade on 2026-01-06 at this same ticker) returned -13.7% over 30 days, but cross-ticker sell history is minimal (1 prior sell, -13.7% avg 30d return vs. 19 prior buys averaging +51.8%), limiting inference about timing skill specific to HROW. The substantial reduction in stake during a period of price weakness and deteriorating momentum warrants examination of whether the company's profitability trajectory supports its current valuation.

10% Owner Opaleye Management sells 20,000 HROW shares at $53.35; reduces stake 22.2% amid stock near 52-week high

Opaleye Management, a 10% owner, sold 20,000 shares (22.2% reduction in holdings) at $53.35 on 2026-01-06, leaving 70,000 shares. The sale occurred at $53.35, only 2.7% below the 52-week high of $54.80, and within the stock's recent upward momentum (90-day change: +36.2%, 30-day change: +5.5%). However, the seller's cross-ticker track record shows 3 prior sells averaging -15.4% 30-day return, which is materially weaker than the cross-ticker buy record (17 prior buys, avg 30d return +15.7%), indicating historical difficulty in timing sell decisions. The company remains unprofitable on a full-year basis despite strong revenue growth (+53.3% annual growth, $71.6M latest quarter), creating ambiguity about whether this sale reflects confidence at an inflated valuation or structural execution concerns.